



Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June 2015

					₹ in Crore
	Particulars	3 months ended			Year Ended
		30/06/2015	31/03/2015	30/06/2014	31/03/2015
		Unaudited	Audited (Refer note 6)	Unaudited	Audited
1	Income from Operations:				
	(a) Gross Sales				
	India	148.23	116.83	121.68	491.53
	Outside India	241.52	251.74	195.98	973.10
	Total	389.75	368.57	317.66	1,464.63
	Less : Excise Duty	4.10	2.90	2.62	11.65
	Net Sales	385.65	365.67	315.04	1,452.98
	(b) Other operating income	5.70	8.48	6.70	27.58
	Total Income from Operations (net)	391.35	374.15	321.74	1,480.56
2	Expenditure				
	(a) Cost of materials consumed	79.39	70.27	58.77	324.97
	(b) Purchases of stock-in-trade	12.83	3.02	6.48	33.11
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	11.14	16.34	14.46	7.34
	(d) Employees benefits expense	59.19	54.69	45.97	200.58
	(e) Depreciation and amortisation expense	10.31	13.23	12.55	51.64
	(f) Other expenses	106.24	96.74	99.14	409.33
	Total expenses	279.10	254.29	237.37	1,026.97
3	Profit from operations before other income, finance costs & tax (1-2)	112.25	119.86	84.37	453.59
4	(a) Other Income	3.02	2.88	2.56	12.66
	(b) Exchange rate difference (Net)	3.56	2.10	1.95	4.14
5	Profit from ordinary activities before finance costs & tax (3+4)	118.83	124.84	88.88	470.39
6	Finance costs	1.17	1.49	1.57	5.92
7	Profit from ordinary activities before exceptional item (5-6)	117.66	123.35	87.31	464.47
8	Exceptional Item	-	8.46	-	8.46
9	Profit from ordinary activities after exceptional item but before tax (7-8)	117.66	114.89	87.31	456.01
10	Tax Expense	33.82	40.75	27.65	146.15
11	Net Profit for the period (9-10)	83.84	74.14	59.66	309.86
12	Paid-up Equity Share Capital	17.69	17.68	17.68	17.68
	Face value of Equity Share - in ₹	2	2	5	2
13	Reserve excluding Revaluation Reserves	NA	NA	NA	823.41
14	Earnings Per Share - not annualised (refer note 3)				
	(a) Basic - in ₹	9.53	8.43	6.79	35.24
	(b) Diluted - in ₹	9.53	8.42	6.78	35.20



A	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	- Number of shares	23,071,491	23,013,741	9,305,495	23,013,741
	- Percentage of shareholding	26.22%	26.17%	26.45%	26.17%
2	Promoters and promoter group shareholding				
	a) Pledged/Encumbered				
	- Number of shares	1,000,000	1,051,250	1,445,500	1,051,250
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	1.54%	1.62%	5.59%	1.62%
	- Percentage of shares (as a % of the total share capital of the company)	1.14%	1.20%	4.11%	1.20%
	b) Non-encumbered				
	- Number of shares	63,929,759	63,878,509	24,426,405	63,878,509
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	98.46%	98.38%	94.41%	98.38%
	- Percentage of shares (as a % of the total share capital of the company)	72.64%	72.63%	69.44%	72.63%
B	INVESTOR COMPLAINTS	3 Months ended 30/06/2015			
	Pending at the beginning of the quarter and remaining unresolved at the end of the quarter	Nil			
	Received and disposed off during the quarter	25			
	Notes :				
1	Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 13 August 2015.				
2	Consolidated financial results includes financial results of the company, its wholly owned subsidiaries and step-down subsidiary prepared in accordance with AS 21.				
3	Company's equity shares of the face value of ₹ 5/- each was split into the equity shares of the face value of ₹ 2/- each during March, 2015. Consequently, as required by AS 20, the Earning per share has been disclosed considering increased number of shares post sub-division, for all periods reported here in above.				
4	During the quarter 57,750 equity shares fully paid-up were allotted upon exercise of vested stock options pursuant to ESOS 2011, including bonus, resulting in increase in paid-up share capital by ₹0.01 cr. and share premium by ₹0.28 cr.				
5	The group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".				
6	Figures for the quarter ended 31 March 2015 are the balancing figures between audited figures for the financial year ended 31 March 2015 and unaudited year to date figures for nine months period ended 31 December 2014.				
7	The Company has opted to publish consolidated financial results from current year, pursuant to option made available as per clause 41 of the listing agreement. The Standalone Financial Results with limited review are available on the company's website www.ajantapharma.com				
8	Standalone Results are as under:				₹ in Crore
	Particulars	3 months ended			Year Ended
		30/06/2015	31/03/2015	30/06/2014	31/03/2015
		Unaudited	Audited	Unaudited	Audited
	Total Income from Operations (net)	340.58	368.84	287.49	1,356.20
	Profit Before Tax	112.61	122.97	84.93	444.88
	Profit After Tax	81.06	84.31	58.72	306.37
9	Previous period's figures have been regrouped wherever necessary.				
					By order of the Board For Ajanta Pharma Ltd.
					
					Yogesh M. Agrawal Managing Director
	Mumbai, 13 August 2015				

Operating Revenue up 22%, PAT up 41%

(Consolidated - 1st Quarter Results, FY 2015-16)

Mumbai, 13th August 2015: Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company reported today its performance for the 1st quarter ended 30th June 2015.

Key financial & performance highlights - Consolidated

- Revenue from operations grew 22% at Rs. 391 cr. against Rs. 322 cr.
- EBITDA growth of 26% at Rs. 123 cr. against Rs. 97 cr., EBITDA at 31% of revenue.
- Profit before tax grew 35% at Rs. 118 cr. against Rs. 87 cr.
- Profit after tax grew 41% at Rs. 84 cr. against Rs. 60 cr., PAT at 21% of revenue.

Key financial & performance highlights - Standalone

- Revenue from operations grew 18% at Rs. 341 cr. against Rs. 287 cr.
- EBITDA growth of 22% at Rs. 110 cr. against Rs. 90 cr., EBITDA at 32% of revenue.
- Profit before tax grew 33% at Rs. 113 cr. against Rs. 85 cr.
- Profit after tax grew 38% at Rs. 81 cr. against Rs. 59 cr., PAT at 24% of revenue.

Commenting on the results, **Mr. Yogesh M. Agrawal, Managing Director** said “We have delivered another quarter of competitive growth and margin improvement ahead of the market. Our strategy remains focused on strengthening the core of our business which is refining the thrust on brand building, increasing the intensity on R&D and continuous improvement of our executional capabilities. We intend to enhance our focus on R&D in coming year to augment our capabilities which will be essential to deliver sustained growth.”

India

For Q1 FY2016, overall India business was Rs. 144 cr., up 21% over Q1 FY2015. Out of this, Indian Branded business was Rs. 128 cr. posting healthy growth of 18% as against the industry growth of 14%. Institution sales was Rs. 16 cr., posting growth of 58% over previous year quarter. During the quarter, 7 new products were launched, out-of-which 2 were first to market.

In the therapeutic segments where we operate, as per IMS MAT June '15, we have posted robust growth of 45% in Cardiology (segment growth of 13%), 46% in Ophthalmology (segment growth of 21%), 20% in Dermatology (segment growth of 20%) and 50% in Pain Management (segment growth of 13%).

Emerging Markets

Emerging markets consolidated business grew 22% during Q1 FY2016 with sale of Rs. 239 cr. Africa contributed Rs. 147 cr., grew 29%, Asia contributed Rs. 89 cr., grew 13% and Latin America contributed Rs. 3 cr., a de-growth of 20%. During the quarter, company launched 9 new products in emerging markets.



Company continues to strengthen its brand presence in various emerging markets it operates in. Company has a pipeline of 1,600+ products under registration paving the way for sustained growth in these markets.

Regulated Markets

Company has recently received 3 more ANDA approvals apart from 2 approvals it had, taking the total approved basket to 5. Company continues to gain market share for its maiden product launched in the US market & propose to launch other 4 products before the end of this financial year. In Q1 FY2016, sale for one single product was Rs. 3 cr. Company has a basket of 25 ANDAs, out of which 20 are awaiting approval from US FDA.

R&D

In order to meet the identified strategic goals of the company we are enhancing the R&D capabilities and capacities. During last 12 months, the head count has gone up from approx. 400 to 500 which is further expected to be ramped up during the year.

As a result of strategically increased focus on R&D, expenses have gone up from Rs. 11 cr. in Q1 FY2015 to Rs. 18 cr. for Q1 FY2016 which is 5% of net sales

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa & India. Many of company's products are first to market and are leading in their sub therapeutic segments.

Company's state of the art R&D centre for formulation development is located at Mumbai, having a team of 500+ people. Company has world class manufacturing facilities - 4 located in India and 1 at Mauritius. One of the manufacturing facilities in India is approved by US FDA, UK MHRA, pre-qualification from WHO, apart from having approval from FDAs of many other countries.

Implementation of new formulation manufacturing facility (oral solids) at Dahej has been completed and is undergoing qualification, after which it will start taking regulatory filing batches. Addition of this facility will ensure that we have adequate capacities to cater to our growths in coming years.

For last 5 years, company has posted healthy performance with its consolidated revenue showing a CAGR of 31% and net profit of 57%.

For more details visit www.ajantapharma.com. You could also follow us on twitter for regular updates - www.twitter.com/ajantapharma

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

